Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study (Q38677321)
Jump to navigation
Jump to search
scientific article published on 13 July 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study |
scientific article published on 13 July 2017 |
Statements
1 reference
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study (English)
1 reference
M Airoldi
V Arcangeli
S Artale
A Ballerio
L Blasi
S Campidoglio
M Ciccarese
M C Cursano
A Fabi
L Ferrari
A Ferzi
C Ficorella
A Frassoldati
A Fumagalli
O Garrone
V Gebbia
D Generali
N La Verde
M Maur
A Michelotti
G Moretti
M Pistelli
M Porpiglia
D Sartori
C Scavelli
A Schirone
A Turletti
M R Valerio
A Zambelli
L Clivio
on behalf of
13 July 2017
1 reference